Recent Annual Reports

Browse the latest SEC filings with AI-powered analysis. Get insights into corporate performance, financial trends, and business developments.

📊 4797 Reports

🤖 AI Analyzed

Recent

📄 Page 259 of 400

LUB LIQUIDATING TRUST

10-K March 9, 2026

Key Highlights

Completed the sale of its entire real estate portfolio in 2025, a major mileston...
Maintains a strong cash position of $10 million with limited liabilities totalin...
Reported an estimated Net Asset Value (NAV) of $0.43 per unit, indicating potent...

Read Analysis

🤖 AI Generated

UBS Group AG

20-F March 9, 2026

Key Highlights

UBS Group AG is a global financial services company based in Switzerland.
Offers a wide range of financial services including wealth management, asset man...
Serves a diverse global client base, from private to institutional and corporate...

Read Analysis

🤖 AI Generated

Voyager Therapeutics, Inc.

10-K March 9, 2026

Key Highlights

Proprietary TRACER™ capsid discovery platform offers a differentiated approach f...
Strategic partnerships with Novartis, Neurocrine, and Alexion provide significan...
Lead partnered program, VY-HTT01 for Huntington's Disease, is now in Phase 1/2 c...

Read Analysis

🤖 AI Generated

Editas Medicine, Inc.

10-K March 9, 2026

Key Highlights

Positive preliminary clinical data for EDIT-301, showing favorable safety and in...
Strong cash position of $420 million as of December 31, 2025, providing an estim...
Strategic refinement to a more focused pipeline, prioritizing programs with the ...

Read Analysis

🤖 AI Generated

ZIM Integrated Shipping Services Ltd.

20-F March 9, 2026

Key Highlights

Significant reduction in future lease obligations for specific vessels from rela...
ZIM operates a global container shipping business across major trade routes, uti...
The company provides a diverse range of container transportation services, inclu...

Read Analysis

🤖 AI Generated

GS Mortgage Securities Trust 2016-GS2

10-K March 9, 2026

Key Highlights

Operates as a Commercial Mortgage-Backed Securities (CMBS) trust, distributing p...
No single borrower accounts for 10% or more of the total outstanding loan balanc...
Midland Loan Services affirmed operational integrity and compliance with Regulat...

Read Analysis

🤖 AI Generated

ARS Pharmaceuticals, Inc.

10-K March 9, 2026

Key Highlights

Neffy achieved its first commercial sale in the U.S. in June 2025, marking ARS P...
Total revenue significantly increased to $15.5 million, driven by initial Neffy ...
The company secured $75.0 million in term loans and maintains a strong liquid as...

Read Analysis

🤖 AI Generated

SPRUCE BIOSCIENCES, INC.

10-K March 9, 2026

Key Highlights

Developing Tralesinidase alfa enzyme replacement therapy (TA-ERT) for rare Sanfi...
Aims for an accelerated approval pathway for TA-ERT to potentially speed up mark...
Potential to expand its pipeline by licensing or acquiring other promising drug ...

Read Analysis

🤖 AI Generated

Dianthus Therapeutics, Inc. /DE/

10-K March 9, 2026

Key Highlights

Lead investigational drug, Claseprubart (C1s inhibitor), is in Phase 2/3 clinica...
Second promising candidate, DNTH212 (oral C3 inhibitor), is in preclinical devel...
Maintained a solid cash position of $160 million as of December 31, 2023, estima...

Read Analysis

🤖 AI Generated

Repay Holdings Corp

10-K March 9, 2026

Key Highlights

Significant financial turnaround: $35M net income from a $10M loss, with 12% rev...
Robust operational expansion: Total processing volume increased 18% to $20 billi...
Strategic growth initiatives: Successful tuck-in acquisition adding $15M in annu...

Read Analysis

🤖 AI Generated

Tri-County Financial Group, Inc.

10-K March 9, 2026

Key Highlights

Total revenue grew 12% and net income increased 15%, demonstrating robust profit...
Strong financial health with ROAA of 1.25%, ROAE of 12.8%, and capital ratios we...
Successful loan portfolio expansion (9% growth) and deposit growth (7%), with no...

Read Analysis

🤖 AI Generated

Boundless Bio, Inc.

10-K March 9, 2026

Key Highlights

Pioneering ecDNA-directed therapies to combat aggressive cancer growth and drug ...
Lead program BBO-1020 is in Phase 1/2 clinical trials, with BBO-001 in preclinic...
Successful Initial Public Offering (IPO) raised $100.0 million, extending operat...

Read Analysis

🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from annual reports with our AI-powered analysis. Track corporate performance, financial trends, and strategic developments.

Back to Homepage